Founder Shahir Barzegar launches a UAE-wide GLP-1 care model under the Hayat Initiative campaign.
Shahriar Shahir Barzegar, Founder of Hoopoe Holding, has announced the launch of a structured clinical framework for GLP-1 therapy delivery across the UAE as part of the ongoing “Hayat Initiative” campaign.
The announcement comes amid rising demand for obesity and metabolic treatments, including injectable therapies such as Mounjaro by Eli Lilly and Company and the expected introduction of oral GLP-1 alternatives in the regional market.
The newly introduced framework will be implemented across Hoopoe Holding’s clinical ecosystem, including Elegant Hoopoe Polyclinic, and is designed to standardise how GLP-1 therapies are prescribed, monitored and integrated into long-term metabolic care pathways.
“The market is moving quickly toward broader access,” Barzegar said. “What we are introducing is a structured clinical layer to ensure that this access translates into safe, measurable and sustainable outcomes.”
The framework is built around three core clinical pillars, including the preservation of muscle mass during weight loss.
The framework is built around three core clinical pillars: muscle mass preservation during weight loss, post-treatment weight stability protocols, and patient selection based on metabolic and hormonal profiling.
According to Hoopoe Holding, the system integrates physician-led assessment, nutritional planning, strength training protocols, and continuous metabolic monitoring into a unified, coordinated care pathway.
The rollout is being executed alongside the Hayat initiative, a UAE-wide awareness campaign developed in collaboration with Eli Lilly and Company and TruBody USA, aimed at reframing obesity as a chronic metabolic condition that requires structured medical intervention.
As part of the implementation, Hoopoe Holding will expand access through its licensed multi-channel infrastructure, including clinic-based care, telehealth, homecare services and mobile medical units, enabling patients to remain within a continuously supervised treatment pathway.
“With new formats such as oral GLP-1 therapies entering the market, accessibility will increase significantly,” said Shahriar Shahir Barzegar. “Our focus is to ensure that the clinical system evolves at the same pace as the science.”
The company confirmed that the framework is already being deployed across its UAE operations, with further expansion planned in line with regulatory guidelines and clinical demand trends.
